T1	MergerAcquisition 172 188	to help fend off
A1	Confidence T1 Certain
A2	MergerAcquisition_NoMergerAcquisition T1
T2	MergerAcquisition 207 226	$ 2.6bn hostile bid
A3	Confidence T2 Certain
A4	MergerAcquisition_NoMergerAcquisition T2
*	in_span_with T2 T1
T3	Company 189 204	GlaxoSmithKline
T4	Company 74 95	Human Genome Sciences
R1	is_about_acquirer Arg1:T1 Arg2:T3	
R2	is_about_target Arg1:T1 Arg2:T4	
T5	SalesVolume 933 978	It claimed substantial potential sales growth
A5	Confidence T5 Certain
A6	SalesVolume_Forecast T5
A7	SalesVolume_Increase T5
T6	Company 791 795	HGSI
R3	is_about_company Arg1:T5 Arg2:T6	
